Introduction
Alzheimer's disease is characterized by the progressive formation in the brain of insoluble amyloid plaques and vascular deposits consisting of the 4 kDa amyloid 13 peptide (AJ~; Glenner and Wong, 1984; Masters et al., 1985) . AI3 is proteolytically derived from a large integral membrane protein, the l~-amyloid precursor protein (J3APP). Four Al3-containing isoforms of 13APP, comprising 695, 714, 751, or 770 amino acids, have been described (Kang et al., 1987; Ponte et al., 1988; Ta.nzi et al., 1988; Kitaguchi et al., 1988; Golde et al., 1990) . The two longer isoforms contain a serine protease inhibitory domain of the Kunitz type. After maturation within the endoplasmic reticulum and Golgi, I3APP undergoes a constitutive "a-secretory" proteolytic cleavage to release the large soluble N-terminal ectodomain (APP,) and create a 10 kDa C-terminal fragment that remains membrane bound (Figure 1 ) (Weidemann et al., 1989; Esch et al., 1990; Oltersdorf et al., 1990; Sisodia et al., 1990) . in this pathway, 13APP is cleaved within the AI3 domain primarily between residues Lys-16 and Leu-17, precluding formation of intact AI3 (Esch et al., 1990) . Recently, it has been shown that alternative cleavage sites within the AI3 region can be used in different cells, suggesting that a-secretase cleavage is likely to involve a diverse set of proteases (Zhong et al., 1994) .
The enzyme(s) responsible for this e-secretory cleavage has not yet been isolated, but indirect evidence suggests that the major form of a-secretase is a membrane-bound enzyme that cleaves ~APP on the plasma membrane (Sisodia, 1992) . It has been suggested that the principal determinants of cleavage are an a-helical conformation around the cleavage site and the distance of the hydrolyzed peptide bond from the membrane, not the primary structure in this region (Sisodia, 1992) . AI3 must be generated by an alternative pathway that involves at least two proteolytic cuts, one at the N-terminus by an enzyme(s) designated 13-secretase and one at the C-terminus by y-secretase ( Figure 1 ). Thus, a potential therapeutic strategy for decreasing A~ deposition in AIzheimer's disease involves inhibition of specific enzymes performing one or both of these cuts.
A~ production and release are normal physiological events. The 4 kDa peptides precipitable by a variety of A~-specific antibodies are normally present in the media of ]3APP-expressing cultured cells and in human and rodent cerebrospinal fluid. Most of these 4 kDa peptides secreted from human kidney 293 cells, human M17 neuroblastoma cells, and human fetal mixed brain cultures indeed start at Asp-1 (Haass et al., 1992b; Shoji et al., 1992; Seubert et al., 1992; Busciglio et al., 1993) and contain approximately 40 amino acids. Interestingly, the amount of AI3 released into conditioned media is markedly increased by a double missense mutation (K595N/M596L; Figu re 1) that occurs in a Swedish Alzheimer's disease family (Mullan et al., 1992) , as seen both in transfected cell lines (Citron et al., 1992; Cai et al., 1993) and in primary skin fibroblasts from patients carrying the mutation (Citron et al., 1994) . In addition to AJ~, a 3 kDa peptide (p3) starting at Leu-17 is constitutively secreted. This peptide appears to be derived by "y-secretase cleavage of the 10 kDa C-terminal fragment of J3APP following secretion of APPs (Haass et al., 1993) . p3 has recently been detected in diffuse plaques in Alzheimer brain tissue (Gowing et al., 1994) .
The precise intracellular site(s) of AI3 generation and the proteases involved in its production are poorly understood. However, recent radiosequencing studies have shown that 13-secretase cleavage occurs at slightly different positions in different cell types. In 293 cells, approximately 80% of A~ produced from wild-type 13APP molecules starts at Asp-l, with the rest beginning at Val(-3) and lie(-6) (Haass et al., 1992b) ; however, in primary skin fibroblasts, wild-type ~APP is metabolized to the Asp-1 form of AJ3 only (Citron et al., 1994) , and in Madin-Darby canine kidney cells, primarily to a form starting at Arg-5 (Haass et al., 1994) . These results suggest that different cell-specific proteases are capable of generating the N-terminus of AJ3.
In this study, the substrate requirements of the proteases (~-secretases) that liberate the N-terminus of AJ3 in B5 (444-592) C7 (67.6-695) The schematic shows I3APP695 with the consensus N-linked glycosylation sites (CHO) and the restriction sites Accl (A), Xhol (X), and Bglll (B). The part of the I3APP molecule removed by the XB deletion is indicated. N, N-terminus; C, C-terminus; vertical bars, plasma membrane; black box, AI3. Solid horizontal lines represent the regions against which antibodies B5, C7, 1963, and R1280 were produced. The amino acid sequence of the A,B region of J3APP is expanded. The position of the Swedish (sw) FAD mutation is indicated. The sites of the ~-, J3-, and 7-secretase cleavages are marked by arrows. The exact site(s) of 7-secretase cleavage is un known, but the majority of AI3 molecules in Alzheimer brain tissue terminate at Val-40 or Ala-42 (Mori et al., 1992; Roher et al., 1993) . The amino acids shown in bold type at the lower left were mutated in this study to the amino acids indicated in plain type; A signifies a deletion.
293 cells and in SK-N-SH human neuroblastoma cells were analyzed. We show that these proteases depend on a membrane-bound I3APP substrate but tolerate changes in the distance of the cleaved peptide bond from the membrane. We define a minimal recognition sequence, document that the major Asp-1 cleaving enzyme is highly sequence specific, and show that the 13-secretase cleavage occurs prior to the 7-secretase cleavage. Further, we show that deletion of the entire cytoplasmic tail of I3APP strongly influences the N-terminal cleavage pattern of wild-type but not of Swedish mutant I~APP, consistent with the idea that the N-terminal cleavage of AJ3 in these two ISAPP forms occurs in two different intracellular compartments. Finally, we discuss the implications of our results for current intensive efforts to develop an assay for a J3-secretase enzyme in human brain and to confirm its identity.
Results

Ap Production Does Not Require the N-Terminal Portion of pAPP
To define a minimal region of [3APP that is obligatory for AI3 N-terminal cleavage in intact human cells, two J3APP695 in-frame deletion constructs, in which the 859 bp fragment from Xhol to Bglll (Figure 1 ) is replaced by a 16 bp synthetic piece of DNA, were analyzed, in these constructs, amino acids 309-589, including the two N-glycosylation sites at 467-469 and 496-498 (Kang et al., 1987) , are deleted. Introduction of this deletion into a plasmid carrying the wild-type I3APP695 cDNA created plasmid XB, while introduction into a plasmid carrying the 13APP895 sequence with the Swedish double missense mutation (Citron et al., 1992) ( Figure 1 ) created plasmid XBsw. Upon transfection, both constructs resulted in the production of A13, p3, and APPs, the latter being about 30 kDa smaller than the respective wild-type protein as a consequence of the deletion ( Figure  2A ). As with full.length I]APP constructs, the Swedish mutation leads to a strong increase in the amount of AI5 (Figure 2A ). This experiment demonstrates that amino acids 309-589 are not specifically required for the 13-and 7-secretory cleavages that generate AI3 in intact cells and are not involved in the increase in A13 production observed in the Swedish mutation. Another internal deletion construct, 13APP6~JAX, in which amino acids 78-305, including the ectodomain phosphorylation site(s), were deleted (Hung and Selkoe, 1994 ) also still allowed AI3 production (Hung and Selkoe, unpublished data) , indicating that almost the entire I3APP ectodomain was dispensable with respect to AI3 production.
Proteolytic Generation of the Ap N-Terminus Tolerates Changes of Distance to the Membrane
It has been postulated that c~-secretase cleaves I3APP at a fixed distance from the membrane (Sisodia, 1992) . To address whether the same is true for the AI~ N-terminal cleavage, we engineered constructs with amino acid deletions between the AI3 cleavage site and the stretch of AI3 amino acids from 18 to 23, near the transmembrane domain that is required for ct-secretase cleavage (Sisodia, 1992) . Two deletion constructs were analyzed: in &5-9 the amino acids RHDSG of AJ3 (601-605 of IBAPPs~5) are deleted, and in A9-12 the amino acids GYEV (605-608) are deleted. Both constructs still led to the production of A13 and p3 peptides, as well as an APPs molecule that is poorly detectable by the R1280 immunoprecipitating antibody, owing to the deletion ( Figure 2B ). This finding demonstrates th at amino acids 5-12 of A13 are dispensable for protease recognition of the N-terminal cleavage site. Together with the results of the XB deletion (Figure 2A ), it appears that the recognition sequence for 13-secretase is limited to a maximum of 11 amino acids (positions 590-600) immediately surrounding the cleavage site. However, we cannot exclude the possibility that residues C-terminal to amino acid 608 might also assist in proper recognition. An analogous insertion construct in which the amino acids IGFEV were inserted after the 7th amino acid of AI5 (position 603) led to a strong decrease in both AJ] and p3, suggesting that this insertion had disrupted the overall structure of the molecule and thereby inhibited both ct-and J3-secretase cleavages (data not shown). Relative to wildtype I3APP, the AI~ bands derived from both deletion constructs displayed decreased mobility ( Figure 2B ). This result suggests that the predominant Met-Asp cleavage site was maintained, independently of its membrane distance. (8) A~ internal deletion constructs. In A5-9, AI3 and p3 run as distinct but very closely spaced bands. Radiosequencing of the upper band confirms that it has A~ sequence (see Figure  3 ). Owing to the deletion of amino acids 9-12 and 5-9 of A~, the C-terminus of APP, is much less well recognized by R1280. The -200 kDa proteins detected in all immunoprecipitations and the -70 kDa protein in (8) are nonspecific proteins that are unrelated to ~APP (Haass et al., 1992b) .
Radiosequencing of A~ from A5-9 and A9-12 transfectants demonstrated that this is indeed the case ( Figures  3A and 3C ). For Al~ from both A5-9 and A9-12, major peaks of 3H-phenylalanine were obtained at positions consistent with an AI~ start at Asp-1 (peak of radioactivity at cycle 4) and the deletion of 5 or 4 amino acids, respectively, between Phe-4 and Phe-19/20 (double peaks of radioactivity at cycles 14/15 or 15/16, respectively). As expected, p3 is not influenced by the deletions, and therefore both constructs show a p3 radiosequencing pattern very similar to the one previously established for wild-type I3APP (Haass et al., 1992b) , with most of p3 starting at . In summary, these data strongly suggest that the N-terminal cleavage generating AI3 can tolerate a decrease of distance of the peptide bond from the membrane.
M e m b r a n e A s s o c i a t i o n o f p A P P Is R e q u i r e d for [~-Secretase C l e a v a g e
Next, we asked whether 13APP must be membrane bound for AJ3 production to occur. To address this question, five constructs were designed ( Figure 4A ), transiently transfected into 293 ceils, and checked for AI~ production ( Figure 4B ). The wild-type J3APP695 construct shows the expected bands of APPs, A~, and p3 ( Figure 4B ). The construct STOP51 contains a stop codon at position 648, after the 51st amino acid from the A[3 start site ( Figure 4A ), thus including virtually the entire ~APP transmembrane domain. This construct produces AJ3 and p3 comparably to the wild type ( Figure 4B ). However, products in the size range of APPs are markedly increased (see below). The construct STOP40 contains a stop codon at position 637, after the 40th amino acid from the AJ3 start ( Figure 4A) . cycle number Thus, the resulting I~APP molecule terminates at the major cleavage position of 7-secretase ( Figure 1 ) and would only need to undergo N-terminal cleavage to generate AIS. This construct also produces very high amounts of material in the APPs size range, but secretes neither AI3 nor p3 ( Figure  4B ). Similar results were obtained with the constructs STOP51sw and STOP40sw, which contain the Swedish mutation in addition to the STOP51 or STOP40 deletion, respectively ( Figure 4B ). The fact that the constructs STOP51 and STOP51sw secrete AI3 while STOP40 and STOP40sw do not strongly suggests that only membrane-bound 13APP can function as a substrate for the AI3 N-terminal protease. Both truncation constructs lack the ~APP cytoplasmic domain, thus excluding the possibility that loss of this region alone causes the complete lack of A~ generation in STOP40 and STOP40sw. The only difference between the constructs is the length of the transmembrane region they contain: STOP40 and STOP40sw contain only 12 amino acids of the predicted 24 amino acid transmembrane domain (Kang et al., 1987) , whereas STOP51 and STOP51 sw contain 23. It is therefore likely that the 15APP of STOP51 and STOP51sw occurs in considerable part as a membranebound molecule, whereas ~APP of STOP40 and STOP40sw does not. To test this prediction, we prepared a set of five dishes each from 293 cells that were either untransfected or transfected with 13APP895, STOP51sw, or STOP40sw constructs. Two dishes from each set were metabolically labeled. The conditioned media of these two dishes were pooled, and one-half was immunoprecipitated with R1280, which is directed against A~l_4o ( Figure 4C ). This precipitation showed again that AI3 and p3 are secreted at levels clearly above the endogenous background by wild typeand STOP51sw-transfected cells but not by STOP40sw-transfected cells. The untransfected cells showed very little material in the APPs size range, the wild type-transfected cells show some APPs, and both the STOP51sw-and STOP40sw-transfected cells have strong bands of similar intensity in that size range ( Figure 4C ). The second half of the conditioned media was immunoprecipitated with 1963, an antibody to AI3 residues 21-37 beyond the a-secretase site that recognizes AI3 and p3 but cannot precipitate APPs ending at the ~-secretase site (Figure 1) . The AI3 and p3 precipitations from the various transfectants using antibody 1963 are similar to those obtained with R1280, with the p3 band being slightly more pronounced relative to the A~ band ( Figure 4C ). However, a clear difference in immunoprecipitated material in the APP, range is obtained with 1963. No material above background is precipitated by 1963 from wild type-transfected cells, indicating that they de not release significant amounts of uncleaved I3APP from the membrane, as expected. In contrast, the STOP51sw-transfected cells clearly show some, and the STOP40sw-transfected cells show much more uncleaved 13APP that has been released intact from the membrane, and can thus be precipitated from the medium with 1963. The STOP40sw construct releases much higher amounts of uncleaved precursor, but produces neither A~ nor p3; the latter, as an endproduct of the a-secretory pathway (Haass et al., 1993) , is predicted to arise solely from membrane-associated I3APP (Sisodia, 1992) .
If these differences in AI~ (and p3) secretion from the STOP51sw and STOP40sw molecules are indeed due to their different levels of retention in cell membranes, one would expect to find full-length $TOP51sw and STOP40sw molecules in comparable amounts in total cell lysates, but only STOP51sw molecules in isolated membrane preparations. Figure 4D shows total cell lysates from the two metabolically labeled dishes immunoprecipitated with the 13APP midregion antibody, B5. All transfectants show the faint endogenous ~APPTsl species. In addition, the wildtype transfectant has a major full-length band representing 13APP695 that migrates at a slightly lower molecular weight, as expected. The I3APP from the STOP51 deletion construct is 48 amino acids shorter than the wild-type molecule, and that from the STOP40 deletion construct is 59 amino acids shorter; bands of accordingly lower molecular weight were indeed detected in these extracts. This result indicates that all constructs produce 13APP molecules of the expected size in detectable amounts.
The remaining three dishes of each transfectant were used to prepare isolated carbonate-extracted membranes (see Experimental Procedures), which were then electrophoresed on SDS gels and immunoblotted with antibody B5 ( Figure 4E ). In all cases, the H'-and N'+O'glycosylated forms of the endogenous I3APP751 were detected. In the I~APP695 wild-type transfectant, the N'+O'-glycosylated band of 13APP (marked by the upper "x" in Figure 4E ) comigrates with the N-glycosylated form of the endogenous 13APPT~. In addition, the N-glycosylated form of the transfected I~APP69s migrating at a slightly lower molecular weight (marked by the lower "x") is clearly detectable. Two bands of lower molecular weight representing the N'-and N'+O'-glycosylated forms of the truncated STOP51sw molecule (marked by dots in Figure 4E ) were detected in the membranes of STOP51sw cells. In contrast, only extremely faint bands, besides the endogenous 13APP751 background proteins, were detected in the STOP40sw deletion transfected cells. Together, Figures 4C-4E demonstrate that STOP40sw and STOP51sw are expressed and detectable in cell lysates. However, only STOP51sw is membrane inserted, and only STOP51sw undergoes the J3-secretase cleavage necessary for AI3 production.
Differential Substrate Requirements for l~-Secretase Cleavage of Wild-Type and Swedish J]APP69s
The data presented in Figure 4 seem to suggest that the whole 13APP C-terminus downstream of amino acid 648 (the endpoint of the STOP51 deletion) is dispensable for the production of A~. However, it has been shown that a deletion of the C-terminus of wild-type I3APP695 downstream from amino acid 653 (AC), including the reinternalization motif NPTY, decreases the amount of Al3 produced in 293 cells (Haass et al., 1993) , and that deletion of the reinternalization sequence YENPTY alone has the same effect in CHO cells (Koo and Squazzo, 1994) . Furthermore, whereas the AC mutation lowers the amount of A~ starting at Asp-l, radiosequencing demonstrates that it significantly increases the amounts of Al~-related peptides starting at Val(-3) (radioactive Phe at cycles 7, 22, and 23) and Arg-5 (radioactive Phe at cycles 15 and 16) relative to the amount of the Asp-1 A~ form in the same cells (Haass et al., 1993) . Radiosequencing of AI~ from STOP51-transfected 293 cells confirmed this observation ( Figure  5A ). Peptides starting at Arg-5 (radioactive Phe at cycles 15 and 16) become the predominant A~ species. Surprisingly, this cytoplasmic deletion effect is not observed in AI~ from STOP51sw-transfected 293 cells ( Figure 5B ). Instead, a homogenous "Asp-1 only" N-terminal cleavage pattern is obtained. This pattern is typical for the effects For the M596V mutation, the amounts of the 10 kDa fragment and p3 seem slightly increased in 293 ceils (C) and strongly increased in SK-N-SH cells (F), probably owing to a compensatory increase in c~-secretase cleavage when ~-secretase cleavage is inhibited.
of the Swedish mutation in full-length I3APP molecules and different from the heterogenous A~ N-terminal cleavages of wild-type [3AP P (Citron et al., 1994) . Thus, whereas deletion of the entire cytoplasmic domain (or the YENPTY reinternalization signal alone) has a clear influence on [3-secretase cleavage of wild-type I3APP, it has little or no effect on 13-secretase cleavage of Swedish I3APP, consistent with the hypothesis that, for the latter molecule, [3-secretase cleavage principally occurs before reinternalization of the precursor.
The N-Terminal Cleavage of Ap Is Highly Sequence Specific
Previous experiments with transient and stable transfections of plasmids carrying the Swedish mutation suggest that amino acid substitutions at or near the N-terminal cleavage site can have profound effects on the amount of AI3 being produced in several types of cells (Citron et al., 1992; Cai et al., 1993) . We therefore analyzed the effects of other amino acid substitutions in the region from Val(-3) (residue 594 of 13APP895) to Ala-2 (residue 598) in transient transfections. The substitution constructs are abbreviated with the letter of the original amino acid, its position number, and the letter of the substituted amino acid; amino acid deletions are indicated by A. As an example of this set of experiments, Figure 6 shows all the I3APP derivatives obtained from the mutants M596V and D597A in both 293 cells and SK-N-SH human neuroblastoma cells. Conditioned media of the transfected cells were precipitated with the APPs-reactive antibody B5, and all three constructs yielded APPs proteins of the same size and in comparable amounts, whether expressed in 293 cells ( Figure 6B ) or SK-N-SH neuroblastoma cells ( Figure 6E ). However, precipitation of the conditioned media with the AJ3-specific antibody R1280 revealed striking differences among the constructs: while all three transfectants produced p3, which started at Leu-17 (data not shown) and is not observed in untransfected SK-N-SH cells, M596V produced no AI3 ( Figures 6A and 6D) . Likewise, D597A did not produce the 4 kDa AI3 species, but instead a -3.8 kDa peptide ( Figures 6A and 6D ) that started at Phe-4
(radiosequencing data not shown). These results were ob- tained in both 293 cells ( Figure 6A ) and SK-N-SH cells ( Figure 6D ) after overnight labeling and were also seen after a 2 hr pulse labeling in the 293 cells (data not shown).
When cell extracts were precipitated with the C-terminal antibody C7, all transfected cells were found to overproduce membrane-bound, full-length 13APP (data not shown) and a 10 kDa C-terminal fragment that remains membrane-bound after release of APP, into the medium (293 cells, Figure 6C ; SK-N-SH cells, Figure 6F ). An additional 12 kDa C-term inal fragment is observed in S K-N-SH neuroblastoma cells transfected with wild-type 13APP69~ ( Figure  6F ). This band becomes much more pronounced in Swedish SK-N-SH transfectants, is barely detectable in the M596V transfectants, and is replaced by a shorter -11.5 kDa band in the D597A transfectant ( Figure 6F ). A C-terminal fragment of similar size has been previously observed to be increased in M17 human neuroblastoma cells transfected with 13APP carrying the Swedish mutation and was thus hypothesized to be an immediate precursor of AI3 that has not yet undergone 7-secretase cleavage (Cai et al., 1993) . Indeed, both the amounts and the size of this fragment correlate with the amounts and the size of AI3 in our various SK-N-SH transfectants (compare Figures  6D and 6F) . Radiosequencing of the Swedish 12 kDa protein confirms that it indeed starts at Asp-1 (major peak of radioactive Phe in cycle 4; Figure 6G ). It seems highly likely that the substitutions examined primarily influence the N-terminal cleavage of AI3 and not other I?,APP proteolytic processing pathways, because we did not observe any substantial differences in cellular full-length ~APP (data not shown) or decreases in total APPs ( Figures 6B  and 6E) .
We next set out to test an extensive panel of N-terminal substitutions for their effect on AI3 production in 293 cells. For each substitution, the R1280 immunoprecipitates of AI3 and p3 are shown in Figure 7 . The relative ratios of A~ to full-length I~APP, determined by phosphorimaging and set as 1.0 for the wild type in each panel, are indicated ( Figure 7) . All of the substitution mutants produced fulllength J3APP and APPs (data not shown). Likewise, p3 was secreted by all of the mutants analyzed, although in varying amounts. In contrast, AI3 production was markedly affected by most substitutions. Changes at V594 strongly decreased AI3 production, whereas no clear effect was observed for two substitutions for K595. Several substitutions at the pl position M596 were analyzed. The previously described M596L substitution of the Swedish mutation (Citron et al., 1992) led to an increase in AlL Of all the other substitutions, only the hydrophobic, bulky residues F and Y did not lead to a strong decrease in AI3 ( Figure 7B ). The AI3 4 kDa species was virtually eliminated by all the D597 substitutions. Only D597E still showed the original AI3 band ( Figure 7C ). However, in all these D597 substitutions, intermediate bands of -3.8 kDa appeared that were not observed from wild-type constructs ( Figure 7C ), as shown above for D597A ( Figure 6D ). Substitutions of A598 also had a marked inhibitory effect on AI3 production (Figure 7D) . In summary, almost all of the single amino acid substitutions at and immediately around the N-terminal cleavage site markedly decreased AI3 production.
Discussion
In this work, we have used human 293 cells to establish the substrate requirements of proteases that cleave I~APP at the N-terminus of AlL We show that three 13APP mutants producing strong, but distinct, effects on AI3 production in this cellular system give essentially identical results in human SK-N-SHneuroblastoma cells. These data suggest that mutations around the Met-Asp cleavage site may lead to similar changes in AI3 production in other neural and nonneural cell types. Our findings demonstrate that the region defined by residues 590-600 (13APPsg~ numbering) is sufficient for recognition and efficient cleavage of the precursor by the AI~ N-terminal protease(s). When the cleavage site is moved 5 amino acids closer to the membrane, there is no effect on cleavage, as demonstrated by N-terminal sequencing of the product. This result suggests that the protease(s), designated 13-secretase(s), recognizes the primary structure around the cleavage site independently of its distance from the membrane, a property which is the opposite of that postulated for (~-secretase (Sisodia, 1992) . The fact that I~-secretases do not require a fixed distance to the membrane in order to cleave suggests that the proteases themselves are not membrane anchored. However, they can only act on membrane-bound 13APP molecules in intact cells, because otherwise the STOP40 and STOP40sw forms of 13APP would give rise to AI3, as do the STOP51 and STOP51sw constructs, which also lack the cytoplasmic domain but contain most of the transmembrane domain. The fact that only membrane-bound 15APP is N-terminally cleaved in vivo implies that AI3 is very unlikely to be produced extracellularly from larger secreted N-or C-terminal fragments of full-length ~APP, at least not by the same proteases that produce AI3 in intact cells.
Two lines of indirect evidence suggest that more than one protease can generate the N-terminus of AI~: first, the wild-type 13APP molecule can be processed into Al3-related peptides starting at different positions in a cell type-dependent manner; second, the N-terminal sequence heterogeneity of AI3 peptides produced in 293 cells suggests the action of more than one enzyme, particularly in view of our finding here that the Met-Asp cleaving enzyme is highly sequence specific. The results of substitutions at the pl position, in which only the large hydrophobic residues Met, Leu, Phe, and Tyr allowed cleavage, are consistent with the primary cleavage at Asp-1 being produced by a chymotryptic-like proteinase. Based on our AI3 sequencing data, this enzyme would be the only one capable of creating the AI~ N-terminus in fibroblasts, would be the predominant enzyme in 293 cells, and would be virtually absent from the normal AI3 production pathway in MadinDarby canine kidney cells (in which AI3 begins primarily at Arg-5). 13APP substrates with mutations around the regular N-terminal cleavage site could then be recognized by other proteases with different specificities. This would explain the 3.8 kDa peptides that arise after virtually any substitution at D597. The situation is complicated further by the fact that not all enzymes capable of cleaving the N-terminus of AI5 need necessarily be located in the same subcellular compartment. It has recently been demonstrated that one site of AI3 generation is within an early endosome following reinternalization of 13APP from the cell surface (Koo and Squazzo, 1994) . However, 13APP molecules such as STOP51, in which the reinternalization signal is deleted, still produce AI3, albeit in reduced amounts and with increased levels of AI],-related peptides starting at positions other than Asp-l.
Most of the single amino acid substitutions we tested substantially decreased or eliminated AI3 production. We believe this result is due to reduced cleavage at the AI3 N-terminus rather than to decreased stability of the peptide or destruction of an epitope essential for the immunoprecipitation, because substitutions at V594 and M596 in front of the cleavage site would not influence antibody recognition or stability of a peptide starting at D597. Furthermore, the loss of the 4 kDa peptide in D597A was also observed in a short-pulse experiment, arguing against AI~ destabilization by substitution as a cause for its reduction in the D597 mutants. The fact that R1280 precipitates p3 shows that it does not recognize solely epitopes at the N-terminus of AlL This makes it unlikely that single amino acid substitutions at the AI3 N-terminus would completely block R1280 binding and thereby account for the disappearance of the 4 kDa band.
Our data underscore the previous conclusion that p3 arises from a different processing pathway than AI3 (Haass et al., 1993) . The fact that only the Swedish mutation, with its M596L substitution, clearly increases AI3 production is consistent with the assumption that the Leu-Asp bond is a much better substrate than the wild-type Met-Asp bond for an Asp-1 cutting protease that cleaves I~APP during its transport to the cell surface. This cleavage would happen prior to the reinternalization that appears to be necessary for the principal Asp-1 cleavage event in the wild-type substrate. Such a model would explain why the cleavage pattern of Swedish 13APP is not affected by C-terminal truncations like STOP51sw that delete the internalization signals. Because none of the other mutants we examined besides M596L led to such a strong increase in AI3 production, we speculate that any other polymorphisms around the cleavage site would also be phenotypically silent, making it unlikely that additional FAD mutations which cause increased AI3 production will be mapped to the N-terminus of AlL
The present investigation describes several properties of the 13-secretase enzymes that produce AI5 in living human cells and also allows two general conclusions about the C-terminal y-secretase cleavage. First, the correlation of the amount of the 12 kDa C-terminal 15APP fragment starting at Asp-1 with the amount of AI3, and the correlation of the amount of the respective 11.5 kDa fragment produced by D597A with the amount of the shortened AI3-type peptide starting at Phe-4 in SK-N-SH cells, confirm the previous suggestion of Cai et al. (1993) that the 12 kDa fragment can serve as the immediate precursor of AI3 and indicate that 13-secretase cleavage occurs before y-secretase cleavage. The 12 kDa molecule has not been observed, however, in transfected 293 cells ( Figure 6C ) (Citron et al., 1992) or in primary skin fibroblasts from patients carrying the Swedish FAD mutation (Citron et al., 1994) , suggesting that there are cell type differences in the rate at which the 12 kDa molecule undergoes y-secretase cleavage. Second, because A~ is still produced from constructs like STOP51sw, "y-secretase does not require the cytoplasmic domain of J3APP to recognize and cleave the C-terminus of AJ~.
Finally, our description of the substrate specificity of the protease has important practical consequences. For example, our data suggest that ~APP recombinant derivatives or synthetic peptides used to identify and characterize this protease must at least include Val-594 to Ala-598. Furthermore, one can now design control substrates with substitutions like M596V, which should not be cleaved well by the candidate protease. However, as we have shown here, only membrane-bound 13APP undergoes N-terminal cleavage in vivo. If this need for membrane anchoring reflects a requirement of the protease rather than a requirement for substrate compartmentalization and targeting, then I~APP derivatives and synthetic peptides that are not membrane bound should not be recognized by the protease for which they are designed. Therefore, the use of synthetic peptides or recombir~ant fragments in solution to screen for ~-secretase might well lead to the isolation of irrelevant enzymes. These various considerations emphasize the importance of acquiring in vivo data in intact human cells when searching for physiologically relevant proteases.
Experimental Procedures
Transfection, Metabolic Labeling, Preparation of Total Cell Lysates, Immunoprecipitation, and Protein Radiosequencing Details of these methods have been described previously (Haass et al., 1992b) . Briefly, subconfluent 10 cm dishes of human embryonic kidney 293 cells or SK-N-SH human neuroblastoma cells were transiently transfected with 20 Hg of supercoiled plasmid DNA using Lipofectin (GIBCO/BRL) as described by the manufacturer. About 48 hr after transfection, cells were metabolically labeled with [3SS]methionine overnight. Immunoprecipitations were performed as described (Haass et al. 1992b ). Immunoprecipitated APP, was separated on a 10% SDS-polyacrylam ide gel, whereas precipitates of A~ and p3 from media and precipitates of cell extracts were separated on 10%-20% TrisTricine gels. Autofluorography was car-led out as described (Haass et al., 1992b) . Bands were quantitated by phosphorimaging, Radioactive sequencing of the 4 kDa (A~,) end 3 kDa (p3) peptides was performed after R1280 immunoprecipitation of transiently transfected cells metabolically labeled with L- [2,3,4,5,6-3H] phenylalanine as described (Haass et al., 1992b) .
